vs
Side-by-side financial comparison of DYNAVAX TECHNOLOGIES CORP (DVAX) and IMAX CORP (IMAX). Click either name above to swap in a different company.
IMAX CORP is the larger business by last-quarter revenue ($125.2M vs $94.9M, roughly 1.3× DYNAVAX TECHNOLOGIES CORP). DYNAVAX TECHNOLOGIES CORP runs the higher net margin — 28.4% vs 0.5%, a 27.9% gap on every dollar of revenue. On growth, IMAX CORP posted the faster year-over-year revenue change (35.1% vs 17.7%). DYNAVAX TECHNOLOGIES CORP produced more free cash flow last quarter ($32.6M vs $28.0M). Over the past eight quarters, DYNAVAX TECHNOLOGIES CORP's revenue compounded faster (30.6% CAGR vs 25.8%).
Dynavax Technologies Corp is a commercial-stage biopharmaceutical company specializing in the research, development, and production of innovative vaccines and immunotherapies for infectious diseases. Its lead approved product is Heplisav-B, an adult hepatitis B vaccine, with core markets in North America and Europe, alongside a pipeline of candidates addressing unmet public health needs.
IMAX Corporation is a Canadian production theatre company which designs and manufactures IMAX cameras and projection systems as well as performing film development, production, post-production and distribution to IMAX-affiliated theatres worldwide. Founded in Montreal in 1967, it has headquarters in the Toronto area, and operations in New York City and Los Angeles.
DVAX vs IMAX — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $94.9M | $125.2M |
| Net Profit | $26.9M | $637.0K |
| Gross Margin | — | 57.6% |
| Operating Margin | 22.4% | 19.3% |
| Net Margin | 28.4% | 0.5% |
| Revenue YoY | 17.7% | 35.1% |
| Net Profit YoY | 53.0% | -88.0% |
| EPS (diluted) | $0.21 | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $125.2M | ||
| Q3 25 | $94.9M | $106.7M | ||
| Q2 25 | $95.4M | $91.7M | ||
| Q1 25 | $68.2M | $86.7M | ||
| Q4 24 | $72.0M | $92.7M | ||
| Q3 24 | $80.6M | $91.5M | ||
| Q2 24 | $73.8M | $89.0M | ||
| Q1 24 | $50.8M | $79.1M |
| Q4 25 | — | $637.0K | ||
| Q3 25 | $26.9M | $20.7M | ||
| Q2 25 | $18.7M | $11.3M | ||
| Q1 25 | $-96.1M | $2.3M | ||
| Q4 24 | $7.0M | $5.3M | ||
| Q3 24 | $17.6M | $13.9M | ||
| Q2 24 | $11.4M | $3.6M | ||
| Q1 24 | $-8.7M | $3.3M |
| Q4 25 | — | 57.6% | ||
| Q3 25 | — | 63.1% | ||
| Q2 25 | — | 58.5% | ||
| Q1 25 | — | 61.4% | ||
| Q4 24 | — | 52.2% | ||
| Q3 24 | — | 55.8% | ||
| Q2 24 | — | 49.4% | ||
| Q1 24 | — | 59.3% |
| Q4 25 | — | 19.3% | ||
| Q3 25 | 22.4% | 27.2% | ||
| Q2 25 | 15.1% | 15.6% | ||
| Q1 25 | -34.7% | 19.3% | ||
| Q4 24 | -2.3% | 10.3% | ||
| Q3 24 | 12.5% | 21.2% | ||
| Q2 24 | 7.0% | 3.2% | ||
| Q1 24 | -35.0% | 15.3% |
| Q4 25 | — | 0.5% | ||
| Q3 25 | 28.4% | 19.4% | ||
| Q2 25 | 19.6% | 12.3% | ||
| Q1 25 | -141.0% | 2.7% | ||
| Q4 24 | 9.8% | 5.7% | ||
| Q3 24 | 21.8% | 15.2% | ||
| Q2 24 | 15.4% | 4.0% | ||
| Q1 24 | -17.2% | 4.1% |
| Q4 25 | — | $0.02 | ||
| Q3 25 | $0.21 | $0.37 | ||
| Q2 25 | $0.14 | $0.20 | ||
| Q1 25 | $-0.77 | $0.04 | ||
| Q4 24 | $0.07 | $0.09 | ||
| Q3 24 | $0.12 | $0.26 | ||
| Q2 24 | $0.08 | $0.07 | ||
| Q1 24 | $-0.07 | $0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $160.2M | $151.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $534.1M | $337.9M |
| Total Assets | $946.5M | $894.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $151.2M | ||
| Q3 25 | $160.2M | $143.1M | ||
| Q2 25 | $99.1M | $109.3M | ||
| Q1 25 | $51.7M | $97.1M | ||
| Q4 24 | $95.9M | $100.6M | ||
| Q3 24 | $119.3M | $104.5M | ||
| Q2 24 | $112.5M | $91.6M | ||
| Q1 24 | $132.0M | $81.0M |
| Q4 25 | — | $337.9M | ||
| Q3 25 | $534.1M | $349.5M | ||
| Q2 25 | $494.2M | $320.4M | ||
| Q1 25 | $530.9M | $299.5M | ||
| Q4 24 | $596.8M | $299.5M | ||
| Q3 24 | $681.4M | $289.4M | ||
| Q2 24 | $642.8M | $267.2M | ||
| Q1 24 | $618.5M | $258.8M |
| Q4 25 | — | $894.0M | ||
| Q3 25 | $946.5M | $889.6M | ||
| Q2 25 | $918.4M | $868.6M | ||
| Q1 25 | $945.9M | $848.3M | ||
| Q4 24 | $986.3M | $830.4M | ||
| Q3 24 | $1.1B | $847.6M | ||
| Q2 24 | $1.0B | $827.4M | ||
| Q1 24 | $986.6M | $824.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $33.8M | $29.4M |
| Free Cash FlowOCF − Capex | $32.6M | $28.0M |
| FCF MarginFCF / Revenue | 34.4% | 22.3% |
| Capex IntensityCapex / Revenue | 1.3% | 1.1% |
| Cash ConversionOCF / Net Profit | 1.26× | 46.11× |
| TTM Free Cash FlowTrailing 4 quarters | $80.5M | $118.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $29.4M | ||
| Q3 25 | $33.8M | $67.5M | ||
| Q2 25 | $23.4M | $23.2M | ||
| Q1 25 | $-19.6M | $7.0M | ||
| Q4 24 | $53.0M | $11.5M | ||
| Q3 24 | $19.5M | $35.3M | ||
| Q2 24 | $10.7M | $35.0M | ||
| Q1 24 | $-16.7M | $-11.0M |
| Q4 25 | — | $28.0M | ||
| Q3 25 | $32.6M | $64.8M | ||
| Q2 25 | $22.0M | $20.9M | ||
| Q1 25 | $-23.6M | $5.3M | ||
| Q4 24 | $49.5M | $6.9M | ||
| Q3 24 | $18.1M | $34.2M | ||
| Q2 24 | $9.9M | $33.5M | ||
| Q1 24 | $-17.4M | $-12.1M |
| Q4 25 | — | 22.3% | ||
| Q3 25 | 34.4% | 60.7% | ||
| Q2 25 | 23.0% | 22.8% | ||
| Q1 25 | -34.6% | 6.1% | ||
| Q4 24 | 68.8% | 7.4% | ||
| Q3 24 | 22.5% | 37.3% | ||
| Q2 24 | 13.5% | 37.6% | ||
| Q1 24 | -34.3% | -15.3% |
| Q4 25 | — | 1.1% | ||
| Q3 25 | 1.3% | 2.6% | ||
| Q2 25 | 1.5% | 2.6% | ||
| Q1 25 | 5.8% | 1.9% | ||
| Q4 24 | 4.8% | 5.0% | ||
| Q3 24 | 1.7% | 1.2% | ||
| Q2 24 | 1.1% | 1.8% | ||
| Q1 24 | 1.5% | 1.4% |
| Q4 25 | — | 46.11× | ||
| Q3 25 | 1.26× | 3.27× | ||
| Q2 25 | 1.25× | 2.06× | ||
| Q1 25 | — | 2.99× | ||
| Q4 24 | 7.52× | 2.16× | ||
| Q3 24 | 1.11× | 2.54× | ||
| Q2 24 | 0.94× | 9.78× | ||
| Q1 24 | — | -3.35× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DVAX
| HEPLISAVB | $90.0M | 95% |
| US Department Of Defense | $4.7M | 5% |
IMAX
| Technology Sales | $46.6M | 37% |
| Image Enhancement And Maintenance Services | $38.1M | 30% |
| Joint Revenue Sharing Arrangement | $20.4M | 16% |
| Maintenance | $16.3M | 13% |
| Finance Income | $2.8M | 2% |
| Other Content Solutions | $1.6M | 1% |
